Abstract

Objective: To compare efficacy of febuxostat 40mg daily with febuxostat 80 mg daily in treating hyperuricemia in patients with chronic kidney disease.
Methodology: This comparative multi-centric study was done from 01-01-2018 to 30-06-2018 on 305 patients of chronic renal failure (S. Creatinine 2.1±0.35) and raised serum uric acid levels were included in the study. It was non-probability consecutive sampling. The patients were in range of 18 to 70 years. They were not on dialysis. A total of 151 patients were given febuxostat 40mg OD and 147 were treated with febuxostat 80mg OD for 4 weeks. Serum uric acid levels of more than 7.0mmol/l in males and 6.0mg/dl in females was labelled as hyperuricemia. Serum uric acid levels were estimated at beginning and end of 4 weeks of treatment. Chi-square test was used for comparison between two groups.
Results: The serum uric acid levels decreased in 68.1% of patients. In febuxostat 80mg OD group, 76.2% patients responded to treatment while in febuxostat 40mg OD group 59.2% achieved target uric acid levels (p=0.025).
Conclusion: Febuxostat 80 mg treated hyperuricemia more effectively than febuxostat 40 mg and did not deteriorate renal functioning.

Key words: Chronic kidney disease, hyperuricemia, efficacy, xanthine oxidase inhibitor, renal insufficiency, febuxostat.